Altan PharmaThursday, 11 June 2015
Byrne Wallace advised Altan Pharma, a private Irish headquartered speciality pharmaceutical company, in connection with the recent investment by a number of international investors and Malin Corporation plc. in Altan Pharma, of which Malin invested €34.5 million for a 65% shareholding in Altan Pharma.
Byrne Wallace also advised as Irish Counsel to Altan Pharma on its acquisition of the GES Group, a privately held group of Spanish injectable drug companies, for a consideration of €87.5 million. Altan also raised debt financing of €40 million in connection with funding the GES Group acquisition.
For further information on this transaction, visit www.malinplc.com or www.altanpharma.com.